TrialBreast cancer research and treatment2013

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.

Denise A Yardley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.